← Eichor
Study identifier: NCT06561308 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer

Condition: Endometrioid Endometrial Cancer  ·  Sponsor: Women's Hospital School Of Medicine Zhejiang University

PhasePhase 2
Planned participants39
Who can joinFemale, 18 Years to 75 Years
Healthy volunteersNo

About this study

Exploring the therapeutic effect of neoadjuvant chemotherapy combined with PD-1 inhibitor camrelizumab on advanced stage III-IV endometrial cancer

This description comes directly from the study's public registry record.

Talk to the study team

Yang Li, PHD  ·  0086-0571-87061501  ·  li_yang@zju.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Women's hospital school of medicine zhejiang universityHangzhou, Zhejiang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06561308